Characterization and demonstration of drug compound ring-chain tautomer formation and its impacts on quality control.

Ottosson, Jenny E; Gränfors, Malin; van Pelt, Sally; Langborg Weinmann, Annika; Nilsson Lill, Sten O; Hulthe, Gustaf; Grönberg, Gunnar

Ottosson, Jenny E; Gränfors, Malin; van Pelt, Sally; Langborg Weinmann, Annika; Nilsson Lill, Sten O; Hulthe, Gustaf; Grönberg, Gunnar.

Afiliação

Ottosson JE; Advanced Drug Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: jenny.ottosson@astrazeneca.com.
Gränfors M; Early Product Development and Manufacturing, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
van Pelt S; Advanced Drug Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Langborg Weinmann A; Early Chemical Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Nilsson Lill SO; Early Product Development and Manufacturing, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Hulthe G; Pharmaceutical Technology and Development, Operations, AstraZeneca, Gothenburg, Sweden.
Grönberg G; Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

J Pharm Biomed Anal ; 198: 114020, 2021 May 10.

Article em En | MEDLINE | ID: mdl-33740606

Assuntos

Contaminação de Medicamentos; Preparações Farmacêuticas; Isomerismo; Espectrometria de Massas; Controle de Qualidade

Palavras-chave

Absorption spectroscopy; Chromatography; Density functional theory; Mass spectrometry; Nuclear magnetic resonance; Tautomer equilibrium

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Preparações Farmacêuticas / Contaminação de Medicamentos Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google